The biotech firm reported quarterly earnings per share of $0.24 and revenue of $106.5 million, aligning with expectations.
Ironwood Pharmaceuticals reported non-GAAP earnings per share of $0.24 and revenue of $106.5 million for the quarter. The results met analyst estimates, reflecting steady performance in its core therapeutic segments.
In the prior quarter, the company posted revenue of $102.3 million and an EPS of $0.22. Year-over-year revenue growth remained modest, driven by demand for its gastrointestinal treatments.
Shares showed limited movement in after-hours trading as investors digested the in-line results.